# A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

> **NCT06917742** · PHASE1 · RECRUITING · sponsor: **Capstan Therapeutics** · enrollment: 64 (estimated)

## Conditions studied

- Healthy Volunteers
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** CPTX2309
- **DRUG:** CPTX2309

## Key facts

- **NCT ID:** NCT06917742
- **Lead sponsor:** Capstan Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-09
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06917742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06917742, "A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06917742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*